TY  - JOUR
AU  - Veljković, Veljko
AU  - Kohler, Heike
AU  - Muller, S
PY  - 2004
UR  - https://vinar.vin.bg.ac.rs/handle/123456789/2804
AB  - This overview briefly summarizes the current status of global AIDS epidemic, especially pointing out how this pandemic looked in the last year of the second millennium. We also give a brief overview of the state of the art in development of AIDS vaccines together with a short summary of the supporting data and obstacles in this development.
T2  - International Reviews of Immunology
T1  - AIDS vaccine: State of the art at the beginning of the third millennium
VL  - 23
IS  - 5-6
SP  - 369
EP  - 381
DO  - 10.1080/08830180490432730
ER  - 

@article{
author = "Veljković, Veljko and Kohler, Heike and Muller, S",
year = "2004",
abstract = "This overview briefly summarizes the current status of global AIDS epidemic, especially pointing out how this pandemic looked in the last year of the second millennium. We also give a brief overview of the state of the art in development of AIDS vaccines together with a short summary of the supporting data and obstacles in this development.",
journal = "International Reviews of Immunology",
title = "AIDS vaccine: State of the art at the beginning of the third millennium",
volume = "23",
number = "5-6",
pages = "369-381",
doi = "10.1080/08830180490432730"
}

Veljković, V., Kohler, H.,& Muller, S.. (2004). AIDS vaccine: State of the art at the beginning of the third millennium. in International Reviews of Immunology, 23(5-6), 369-381.
https://doi.org/10.1080/08830180490432730

Veljković V, Kohler H, Muller S. AIDS vaccine: State of the art at the beginning of the third millennium. in International Reviews of Immunology. 2004;23(5-6):369-381.
doi:10.1080/08830180490432730 .

Veljković, Veljko, Kohler, Heike, Muller, S, "AIDS vaccine: State of the art at the beginning of the third millennium" in International Reviews of Immunology, 23, no. 5-6 (2004):369-381,
https://doi.org/10.1080/08830180490432730 . .

TY  - JOUR
AU  - Veljković, Veljko
AU  - Muller, S
AU  - Kohler, Heike
PY  - 2003
UR  - https://vinar.vin.bg.ac.rs/handle/123456789/2632
T2  - Lancet
T1  - Does VaxGen hide the breakthrough infections?
VL  - 361
IS  - 9370
SP  - 1743
EP  - 1744
DO  - 10.1016/S0140-6736(03)13344-2
ER  - 

@article{
author = "Veljković, Veljko and Muller, S and Kohler, Heike",
year = "2003",
journal = "Lancet",
title = "Does VaxGen hide the breakthrough infections?",
volume = "361",
number = "9370",
pages = "1743-1744",
doi = "10.1016/S0140-6736(03)13344-2"
}

Veljković, V., Muller, S.,& Kohler, H.. (2003). Does VaxGen hide the breakthrough infections?. in Lancet, 361(9370), 1743-1744.
https://doi.org/10.1016/S0140-6736(03)13344-2

Veljković V, Muller S, Kohler H. Does VaxGen hide the breakthrough infections?. in Lancet. 2003;361(9370):1743-1744.
doi:10.1016/S0140-6736(03)13344-2 .

Veljković, Veljko, Muller, S, Kohler, Heike, "Does VaxGen hide the breakthrough infections?" in Lancet, 361, no. 9370 (2003):1743-1744,
https://doi.org/10.1016/S0140-6736(03)13344-2 . .

TY  - JOUR
AU  - Veljković, Veljko
AU  - Muller, S
AU  - Kohler, Heike
PY  - 2003
UR  - https://vinar.vin.bg.ac.rs/handle/123456789/2665
AB  - Research and clinical data reported during last 10 years indicate the possibility that AIDS vaccines based on the HIV-1 envelope protein gp120 may be worse then useless. A correct assessment of the safety of these AIDS vaccines can not be possible without data which will allow comparison of the disease status between breakthrough HIV infected vaccinated volunteers and those from the control group. Results of the recently finished clinical trial of AIDSVAX represent a good base for this important analysis. (C) 2003 Elsevier Science Ltd. All rights reserved.
T2  - Vaccine
T1  - AIDSVAX results: an important open question
VL  - 21
IS  - 25-26
SP  - 3528
EP  - 3529
DO  - 10.1016/S0264-410X(03)00324-4
ER  - 

@article{
author = "Veljković, Veljko and Muller, S and Kohler, Heike",
year = "2003",
abstract = "Research and clinical data reported during last 10 years indicate the possibility that AIDS vaccines based on the HIV-1 envelope protein gp120 may be worse then useless. A correct assessment of the safety of these AIDS vaccines can not be possible without data which will allow comparison of the disease status between breakthrough HIV infected vaccinated volunteers and those from the control group. Results of the recently finished clinical trial of AIDSVAX represent a good base for this important analysis. (C) 2003 Elsevier Science Ltd. All rights reserved.",
journal = "Vaccine",
title = "AIDSVAX results: an important open question",
volume = "21",
number = "25-26",
pages = "3528-3529",
doi = "10.1016/S0264-410X(03)00324-4"
}

Veljković, V., Muller, S.,& Kohler, H.. (2003). AIDSVAX results: an important open question. in Vaccine, 21(25-26), 3528-3529.
https://doi.org/10.1016/S0264-410X(03)00324-4

Veljković V, Muller S, Kohler H. AIDSVAX results: an important open question. in Vaccine. 2003;21(25-26):3528-3529.
doi:10.1016/S0264-410X(03)00324-4 .

Veljković, Veljko, Muller, S, Kohler, Heike, "AIDSVAX results: an important open question" in Vaccine, 21, no. 25-26 (2003):3528-3529,
https://doi.org/10.1016/S0264-410X(03)00324-4 . .

TY  - JOUR
AU  - Veljković, Veljko
AU  - Metlaš, Radmila
AU  - Kohler, Heike
AU  - Urnovitz, HB
AU  - Prljić, Jelena
AU  - Veljković, Nevena V.
AU  - Johnson, Emmett
AU  - Muller, S
PY  - 2001
UR  - https://vinar.vin.bg.ac.rs/handle/123456789/2419
AB  - Current expansion of AIDS pandemic significantly accelerates AIDS vaccine research resulting in development and clinical testing of several AIDS vaccine candidates. At the same time, available experimental and clinical data demonstrate that current AIDS vaccine strategy is unsuccessful resulting in development of inefficient and harmful vaccines. This overview briefly summarizes reported results which point out the requirement for moratorium on the current clinical trials of HIV-1 gp120/160 vaccines and urgent need for development of a new, efficient and safe AIDS vaccine strategy. (C) 2001 Elsevier Science Ltd. All rights reserved.
T2  - Vaccine
T1  - AIDS epidemic at the beginning of the third millennium: time for a new AIDS vaccine strategy
VL  - 19
IS  - 15-16
SP  - 1855
EP  - 1862
DO  - 10.1016/S0264-410X(00)00194-8
ER  - 

@article{
author = "Veljković, Veljko and Metlaš, Radmila and Kohler, Heike and Urnovitz, HB and Prljić, Jelena and Veljković, Nevena V. and Johnson, Emmett and Muller, S",
year = "2001",
abstract = "Current expansion of AIDS pandemic significantly accelerates AIDS vaccine research resulting in development and clinical testing of several AIDS vaccine candidates. At the same time, available experimental and clinical data demonstrate that current AIDS vaccine strategy is unsuccessful resulting in development of inefficient and harmful vaccines. This overview briefly summarizes reported results which point out the requirement for moratorium on the current clinical trials of HIV-1 gp120/160 vaccines and urgent need for development of a new, efficient and safe AIDS vaccine strategy. (C) 2001 Elsevier Science Ltd. All rights reserved.",
journal = "Vaccine",
title = "AIDS epidemic at the beginning of the third millennium: time for a new AIDS vaccine strategy",
volume = "19",
number = "15-16",
pages = "1855-1862",
doi = "10.1016/S0264-410X(00)00194-8"
}

Veljković, V., Metlaš, R., Kohler, H., Urnovitz, H., Prljić, J., Veljković, N. V., Johnson, E.,& Muller, S.. (2001). AIDS epidemic at the beginning of the third millennium: time for a new AIDS vaccine strategy. in Vaccine, 19(15-16), 1855-1862.
https://doi.org/10.1016/S0264-410X(00)00194-8

Veljković V, Metlaš R, Kohler H, Urnovitz H, Prljić J, Veljković NV, Johnson E, Muller S. AIDS epidemic at the beginning of the third millennium: time for a new AIDS vaccine strategy. in Vaccine. 2001;19(15-16):1855-1862.
doi:10.1016/S0264-410X(00)00194-8 .

Veljković, Veljko, Metlaš, Radmila, Kohler, Heike, Urnovitz, HB, Prljić, Jelena, Veljković, Nevena V., Johnson, Emmett, Muller, S, "AIDS epidemic at the beginning of the third millennium: time for a new AIDS vaccine strategy" in Vaccine, 19, no. 15-16 (2001):1855-1862,
https://doi.org/10.1016/S0264-410X(00)00194-8 . .